围术期静脉利多卡因用于择期结直肠手术胃肠恢复与镇痛:系统综述与更新荟萃分析
该系统综述与荟萃分析纳入12项RCT共1208例接受微创结直肠手术的成人患者,评估围术期静脉利多卡因对比安慰剂的效果。利多卡因显著减少术后恶心呕吐、缩短首次排便和排气时间、降低24小时疼痛评分,但未显著影响术后肠麻痹、住院时间或阿片类药物消耗。
要点
- 静脉利多卡因减少术后恶心呕吐(RR=0.66)。
- 缩短首次排便时间约12.65小时、排气时间约7.08小时。
- 未显著改善肠麻痹、住院时间或阿片消耗。
核心结论
- 围术期静脉利多卡因可适度改善微创结直肠手术后的胃肠恢复和早期疼痛,但不影响肠麻痹、住院时间或阿片使用。
- 常规使用应谨慎,需等待进一步高质量试验。
研究设计与样本
- 系统综述与更新荟萃分析,检索PubMed、Embase和Cochrane Central至2025年6月。
- 纳入比较静脉利多卡因与安慰剂在成人腹腔镜或机器人结直肠手术中的RCT。
- 共纳入12项RCT,1208例患者(利多卡因组603例,安慰剂组605例)。
主要发现
- 利多卡因显著减少术后恶心呕吐(RR=0.66,95%CI 0.45-0.97)。
- 缩短首次排便时间(MD=-12.65小时,95%CI -21.87至-3.43)和首次排气时间(MD=-7.08小时,95%CI -12.85至-1.31)。
- 24小时疼痛评分更低(MD=-1.61,95%CI -2.82至-0.41)。
- 术后肠麻痹(RR=1.01,95%CI 0.69-1.49)、住院时间(MD=-0.37天,95%CI -0.92至0.18)和阿片消耗(MD=0.47,95%CI -10.39至11.32)无显著差异。
临床怎么用
- 可考虑将围术期静脉利多卡因作为微创结直肠手术多模式镇痛与促进胃肠恢复的辅助手段。
- 不应期望其缩短住院时间或减少阿片消耗,常规使用需个体化权衡。
局限性
- 纳入研究存在中至高度异质性。
- 结论受一项大型试验撤稿后的证据不确定性影响。
- 需进一步高质量试验确认获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Minimally invasive colorectal surgery, including laparoscopic and robotic techniques, has enhanced perioperative safety and recovery. However, postoperative gastrointestinal dysfunction remains frequent, delaying discharge and impairing outcomes. Intravenous lidocaine, owing to its analgesic and anti-inflammatory properties, has been proposed to improve recovery, but evidence remains inconsistent, especially after the retraction of a major trial. This updated systematic review and meta-analysis assessed the effects of perioperative intravenous lidocaine on gastrointestinal and clinical outcomes after minimally invasive colorectal resections. METHODS: A systematic search of PubMed, Embase, and Cochrane Central was performed through June 2025. Randomized controlled trials comparing intravenous lidocaine with placebo in adults undergoing laparoscopic or robotic colorectal surgery were included. Two reviewers independently screened studies, extracted data, and evaluated bias using the Cochrane RoB 2 tool. Pooled risk ratios (RR) and mean differences (MD) were calculated with I2 for heterogeneity, and sensitivity analyses were performed. RESULTS: Twelve RCTs involving 1208 patients (603 lidocaine, 605 placebo) met inclusion criteria. Lidocaine significantly reduced postoperative nausea and vomiting (RR = 0.66, 95% CI 0.45-0.97), shortened time to first bowel movement (MD = - 12.65 h, 95% CI - 21.87 to - 3.43), and decreased time to first flatus (MD = - 7.08 h, 95% CI - 12.85 to - 1.31). Pain scores at 24 h were lower (MD = - 1.61, 95% CI - 2.82 to - 0.41). No significant effects were observed for postoperative ileus (RR = 1.01, 95% CI 0.69-1.49), hospital stay (MD = - 0.37 days, 95% CI - 0.92 to 0.18), or opioid consumption (MD = 0.47, 95% CI - 10.39 to 11.32). Results remained robust despite moderate-to-high heterogeneity. CONCLUSIONS: Perioperative intravenous lidocaine modestly improves gastrointestinal recovery and early postoperative pain after minimally invasive colorectal surgery but does not affect ileus, hospital stay, or opioid use. Routine use should be considered cautiously pending further high-quality trials.
引用
- de Paiva MECB, Bezerra FJL, Baldo LT, et al. Perioperative intravenous lidocaine for gastrointestinal recovery and pain control in elective colorectal surgery: a systematic review and updated meta-analysis of randomized controlled trials. Surg Endosc. 2026. PMID: 42554867. doi:10.1007/s00464-026-13096-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。